Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib vs Midostaurin in Newly Diagnosed FLT3-mutated AML or MDS-EB2
NCT04027309Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Dec 2019
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 3 trial of gilteritinib in acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2 (MDS-EB-2), sponsored by HOVON. Started Dec 2019; status: active, not recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
Beyond the preview
Go deeper on NCT04027309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027309.